Non-steroidal anti-inflammatory ligands

Etoricoxib-d 4 is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor , with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.Form:Solid.

Flurbiprofen-d 5 is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the

Flurbiprofen-d 5 is the deuterium labeled Flurbiprofen. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties Furprofen acts via the inhibition of prostaglandin (PGE) synthesis . Furprofen can be treated orally for the relief of painForm:OilIC50&amp: Target:PGE.

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties Furprofen acts via the inhibition of prostaglandin (PGE) synthesis . Furprofen can be treated orally for the relief of painForm:OilIC50&amp: Target:PGE.

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties Furprofen acts via the inhibition of prostaglandin (PGE) synthesis . Furprofen can be treated orally for the relief of painForm:OilIC50&amp: Target:PGE.

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties Furprofen acts via the inhibition of prostaglandin (PGE) synthesis . Furprofen can be treated orally for the relief of painForm:OilIC50&amp: Target:PGE.

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties Furprofen acts via the inhibition of prostaglandin (PGE) synthesis . Furprofen can be treated orally for the relief of painIC50&amp: Target:PGE.

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor

GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonistIn VivoGDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor